About West Pharmaceutical Services Inc
- Industry: Life Sciences Tools & Services
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.westpharma.com/
Frequently Asked Questions
What is the 52-week range for WST?
The 52-week high is $386 and the 52-week low is $223.83.
What is the P/E ratio for WST?
The Price to Earnings (P/E) ratio is 46.60.
What is the dividend yield for WST?
The indicated annual dividend yield is 0.33%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 18.51%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 16.98%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.23.
Analyst Recommendation Trends
Wall Street analyst consensus for WST over the last few months:
Latest WST News
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
ITGR's $127-a-share KKR deal offers defined cash value, while core franchises face slow new-product adoption.
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.
Best Dividend Aristocrats For October 2026
The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Check out the Aristocrats list here.
Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup
VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing
VEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says
West Pharmaceutical Services (WST) could see earnings per share upside of at least 10% to current Wa
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded MetLife, Brinker, Plexus, West Pharma and Omeros, raising ratings and price targets.
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400
Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
1 Surging Stock with Solid Fundamentals and 2 That Underwhelm
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Layoffs, Cyber Disruptions, Annex 1 Upgrades Might Change The Case For Investing In West (WST)
West Pharmaceutical Services recently announced it will phase out a product line at its Scottsdale facility by the end of September, resulting in 98 layoffs and related manufacturing work being shifted to other Becton, Dickinson and Co. locations. At the same time, the company’s push into higher-value products and Annex 1-related sterility upgrades is being tempered by cyber incident disruptions in its West Vantage segment and tariff- and commodity-driven cost pressures. We’ll now examine...
What Is Drawing Attention To West Pharmaceutical Services (WST)?
West Pharmaceutical Services (WST) is juggling mixed signals after recent updates on its business outlook. Investors now have to balance long-term growth drivers with fresh headwinds from a cyber incident, cost inflation, and a Scottsdale product line shutdown. Recent price action reflects that push and pull. The share price is up 9.89% over the past 90 days and 31.08% year to date, while the 1-year total shareholder return of 42.61% contrasts with a slightly negative 3-year total shareholder...
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
Here's Why You Should Add Avantor Stock to Your Portfolio for Now
AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
Intuitive Surgical's CE mark expands da Vinci SP into transvaginal gynecology in Europe, opening a new women's health opportunity and growth runway.
Is West Pharmaceutical Services Stock Outperforming the Nasdaq?
West Pharmaceutical Services has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Intuitive Surgical's da Vinci meta-analysis across 14 million procedures found better perioperative outcomes versus laparoscopic and open surgery.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 8:30 AM EDTCompany ParticipantsRobert...
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock Down
Cooper Companies' Q3 EPS beats estimates as expense controls offset softer revenues, while U.S. inventory cuts pressure CooperVision and weigh on shares.
3 Profitable Stocks with Warning Signs
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Wells Fargo 21st Annual Healthcare Conference September 10, 2026 8:45 AM EDTCompany ParticipantsRobert McMahon -...
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance
GEHC moves StarGuide GX closer to the U.S. market with an FDA 510(k) submission, advancing its next-generation molecular imaging push.
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415
UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?
COO Q3 earnings are likely to benefit from CooperVision strength, improving fertility trends and efficiency gains offsetting Asia-Pacific pressure.
PACS Expands Florida Footprint With 32-Facility Acquisition
PACS plans to acquire operations of 32 Florida skilled nursing facilities, adding 4,049 licensed beds and establishing a statewide network.
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.
Philips Expands Women's Health Ultrasound Portfolio With New Transducer
PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?
Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in […]
West Pharmaceutical Services (WST) And The GLP 1 Story Behind Its Fair Value Gap
How West Pharmaceutical Services stock has been performing West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at US$339.97 on 3 September 2026. The company shows mixed returns over different periods, including gains over the past year alongside shorter term pullbacks. For West Pharmaceutical Services, the recent 1-day share price decline of 0.81% and 3.15% share price pullback over 30 days sit against a much stronger...
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.
Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC
PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Favorite Annette F | -2,524 | - | - |
| 2026-09-15 | Favorite Annette F | -2,524 | $365 | $921,260 |
| 2026-09-15 | Favorite Annette F | +2,524 | $89.64 | $226,251 |
| 2026-09-14 | Favorite Annette F | -2,500 | - | - |
| 2026-09-14 | Favorite Annette F | -2,500 | $355 | $887,500 |
| 2026-09-14 | Favorite Annette F | +2,500 | $89.64 | $224,100 |
| 2026-09-11 | Favorite Annette F | -2,500 | - | - |
| 2026-09-11 | Favorite Annette F | -2,500 | $345 | $862,500 |
| 2026-09-11 | Favorite Annette F | +2,500 | $89.64 | $224,100 |
| 2026-09-08 | Lagarde Michel | +3,600 | - | - |
| 2026-09-08 | Lagarde Michel | +4,950 | - | - |
| 2026-09-08 | Lagarde Michel | +6,200 | - | - |
| 2026-09-08 | Lagarde Michel | +12,088 | - | - |
| 2026-09-08 | Lagarde Michel | +11,081 | - | - |
| 2026-09-08 | Lagarde Michel | +13,879 | - | - |
| 2026-09-08 | Favorite Annette F | -2,500 | - | - |
| 2026-09-08 | Favorite Annette F | -2,818 | - | - |
| 2026-09-08 | Favorite Annette F | -2,817 | - | - |
| 2026-09-08 | Favorite Annette F | -2,500 | $340.81 | $852,025 |
| 2026-09-08 | Favorite Annette F | +2,500 | $89.64 | $224,100 |
| 2026-09-08 | Favorite Annette F | -2,818 | $340.81 | $960,403 |
| 2026-09-08 | Favorite Annette F | +2,818 | $83.47 | $235,218 |
| 2026-09-08 | Favorite Annette F | -2,817 | $340.81 | $960,062 |
| 2026-09-08 | Favorite Annette F | +2,817 | $83.47 | $235,135 |
| 2026-08-11 | McMahon Robert W. | -794 | - | - |
| 2026-08-11 | McMahon Robert W. | -6,355 | - | - |
| 2026-08-11 | McMahon Robert W. | -2,764 | $351.37 | $971,187 |
| 2026-08-11 | McMahon Robert W. | +6,355 | - | - |
| 2026-08-11 | McMahon Robert W. | -346 | $351.37 | $121,574 |
| 2026-08-11 | McMahon Robert W. | +794 | - | - |
| 2026-06-30 | HAUGEN JANET BRUTSCHEA | +46 | $359 | $16,514 |
| 2026-05-12 | Campbell Shane Alden | -474 | - | - |
| 2026-05-12 | Campbell Shane Alden | -296 | - | - |
| 2026-05-12 | Campbell Shane Alden | -135 | $312.07 | $42,129 |
| 2026-05-12 | Campbell Shane Alden | +474 | - | - |
| 2026-05-12 | Campbell Shane Alden | -84 | $312.07 | $26,214 |
| 2026-05-12 | Campbell Shane Alden | +296 | - | - |
| 2026-05-04 | FRIEL ROBERT F | +791 | - | - |
| 2026-05-04 | Feehery William F | +791 | - | - |
| 2026-05-04 | Pucci Paolo | +791 | - | - |
| 2026-05-04 | Michels Douglas A | +791 | - | - |
| 2026-05-04 | Lockhart Stephen H | +791 | - | - |
| 2026-05-04 | LAI GOLDMAN MYLA | +791 | - | - |
| 2026-05-04 | Keller Deborah L | +791 | - | - |
| 2026-05-04 | Joseph Molly | +791 | - | - |
| 2026-05-04 | HAUGEN JANET BRUTSCHEA | +791 | - | - |
| 2026-05-04 | BUTHMAN MARK A | +791 | - | - |
| 2026-04-27 | Favorite Annette F | -2,817 | - | - |
| 2026-04-27 | Favorite Annette F | -2,817 | $305.2018 | $859,753 |
| 2026-04-27 | Favorite Annette F | +2,817 | $83.47 | $235,135 |
| 2026-04-27 | Winters Chad | -896 | - | - |
| 2026-04-27 | Winters Chad | -896 | $300.6688 | $269,399 |
| 2026-04-27 | Winters Chad | +896 | $173.22 | $155,205 |
| 2026-03-31 | HAUGEN JANET BRUTSCHEA | +52 | $250.64 | $13,033 |
| 2026-03-01 | Finch Norman D. Jr. | +3,057 | - | - |
| 2026-03-01 | Finch Norman D. Jr. | +1,285 | - | - |
| 2026-03-01 | Green Eric Mark | +16,630 | - | - |
| 2026-03-01 | Green Eric Mark | +6,986 | - | - |
| 2026-03-01 | Favorite Annette F | +1,712 | - | - |
| 2026-03-01 | Favorite Annette F | +720 | - | - |
| 2026-03-01 | Campbell Shane Alden | +2,691 | - | - |
| 2026-03-01 | Campbell Shane Alden | +1,131 | - | - |
| 2026-03-01 | McMahon Robert W. | +7,337 | - | - |
| 2026-03-01 | McMahon Robert W. | +3,082 | - | - |
| 2026-03-01 | Poussot Rodolphe Jean | +1,040 | - | - |
| 2026-03-01 | Poussot Rodolphe Jean | +437 | - | - |
| 2026-03-01 | Winters Chad | +808 | - | - |
| 2026-03-01 | Winters Chad | +340 | - | - |
| 2026-02-20 | Poussot Rodolphe Jean | -383 | - | - |
| 2026-02-20 | Poussot Rodolphe Jean | -130 | $241.12 | $31,346 |
| 2026-02-20 | Poussot Rodolphe Jean | +383 | - | - |
| 2026-02-20 | Witherspoon Charles | -60 | - | - |
| 2026-02-20 | Witherspoon Charles | -22 | $241.12 | $5,305 |
| 2026-02-20 | Witherspoon Charles | +60 | - | - |
| 2026-02-20 | Winters Chad | -89 | - | - |
| 2026-02-20 | Winters Chad | -30 | $241.12 | $7,234 |
| 2026-02-20 | Winters Chad | +89 | - | - |
| 2026-02-18 | Poussot Rodolphe Jean | -82 | - | - |
| 2026-02-18 | Poussot Rodolphe Jean | -28 | $248.26 | $6,951 |
| 2026-02-18 | Poussot Rodolphe Jean | +82 | - | - |
| 2026-02-18 | Green Eric Mark | -1,319 | - | - |
| 2026-02-18 | Green Eric Mark | -574 | $248.26 | $142,501 |
| 2026-02-18 | Green Eric Mark | +1,319 | - | - |
| 2026-02-18 | Favorite Annette F | -135 | - | - |
| 2026-02-18 | Favorite Annette F | -36 | $248.26 | $8,937 |
| 2026-02-18 | Favorite Annette F | +135 | - | - |
| 2026-02-17 | Witherspoon Charles | -42 | $243.19 | $10,214 |
| 2026-02-17 | Witherspoon Charles | +116 | - | - |
| 2026-02-17 | Winters Chad | -51 | $243.19 | $12,403 |
| 2026-02-17 | Winters Chad | +150 | - | - |
| 2026-02-17 | Green Eric Mark | -1,305 | $243.19 | $317,363 |
| 2026-02-17 | Green Eric Mark | +4,419 | - | - |
| 2026-02-17 | Favorite Annette F | -150 | $243.19 | $36,479 |
| 2026-02-17 | Favorite Annette F | +442 | - | - |
| 2026-02-11 | McMahon Robert W. | -4,231 | - | - |
| 2026-02-11 | McMahon Robert W. | -1,250 | $246.16 | $307,700 |
| 2026-02-11 | McMahon Robert W. | +4,231 | - | - |
| 2025-12-31 | HAUGEN JANET BRUTSCHEA | +46 | $275.14 | $12,656 |
| 2025-12-08 | Finch Norman D. Jr. | +459 | $269.08 | $123,508 |
| 2025-12-08 | Finch Norman D. Jr. | +192 | - | - |